Patents by Inventor Pilar Garin-Chesa
Pilar Garin-Chesa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9274120Abstract: The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor.Type: GrantFiled: March 21, 2014Date of Patent: March 1, 2016Assignee: Boehringer Ingelheim International GmbHInventors: Guenther Adolf, Pilar Garin-Chesa, Ulrich Hirt
-
Publication number: 20140205592Abstract: The present invention relates to a method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. Said detection of the expression of the E-cadherin protein in a cancer sample of a cancer patient is preferably conducted by way of an immunohistochemistry (IHC) method. Said IHC method preferably employs a primary antibody which is specific for E-cadherin and a secondary antibody which specifically reacts with the primary antibody. The present invention also relates to a method of treating a cancer patient whose cancer is characterized by an E-cadherin protein immunoreactivity score (IRS) of 0-2, comprising administering to the patient a therapeutically effective amount of a PTK2 inhibitor.Type: ApplicationFiled: March 21, 2014Publication date: July 24, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Guenther ADOLF, Pilar GARIN-CHESA, Ulrich HIRT
-
Publication number: 20140187563Abstract: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.Type: ApplicationFiled: March 6, 2014Publication date: July 3, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Joanne VAN RYN, Frank HILBERG, Pilar GARIN-CHESA
-
Publication number: 20140066456Abstract: The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne VAN RYN, Pilar GARIN-CHESA, Flavio SOLCA
-
Publication number: 20120244141Abstract: A method for determining whether a cancer patient is susceptible to treatment with a protein tyrosine kinase 2 (PTK2) inhibitor, comprising detecting the expression of the E-cadherin protein in a cancer sample of said cancer patient, wherein an E-cadherin protein immunoreactivity score (IRS) of 0-2 indicates that the cancer patient is susceptible to treatment with a PTK2 inhibitor. The invention further encompasses treatment of a patient with a protein tyrosine kinase 2 (PTK2) inhibitor if it has been so determined that said patient is susceptible to such treatment.Type: ApplicationFiled: September 20, 2011Publication date: September 27, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Guenther ADOLF, Pilar GARIN-CHESA, Ulrich HIRT
-
Publication number: 20120142703Abstract: The invention relates to new methods for the treatment of oncological and fibrotic disease comprising the combined administration of an inhibitor of vascular endothelial growth factor receptors (VEGFRs) in conjunction with a thrombin inhibitor.Type: ApplicationFiled: May 11, 2010Publication date: June 7, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne Van Ryn, Frank Hilberg, Pilar Garin-Chesa
-
Publication number: 20120136004Abstract: The invention relates to new methods for the treatment of oncological and fibrotic diseases comprising the combined administration of a receptor tyrosine kinase inhibitor in conjunction with a thrombin inhibitor.Type: ApplicationFiled: May 11, 2010Publication date: May 31, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Joanne Van Ryn, Pilar Garin-Chesa, Flavio Solca
-
Patent number: 7714010Abstract: The invention relates to pyrrolobenzimidazolone compounds of formula (I), wherein A, T and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.Type: GrantFiled: May 17, 2005Date of Patent: May 11, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Darryl McConnel, Steffen Steurer, Bernd Krist, Ulrike Weyer-Czernilofsky, Maria Impagnatiello, Matthias Treu, Iris Kauffmann-Hefner, Pilar Garin-Chesa, Andreas Schnapp
-
Publication number: 20050261350Abstract: The invention relates to pyrrolobenzimidazolone compounds of formula (I), wherein A, T and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation and the use thereof for preparing a pharmaceutical composition.Type: ApplicationFiled: May 17, 2005Publication date: November 24, 2005Applicant: Boehringer Ingelheim International GmbHInventors: Darryl McConnel, Steffen Steurer, Bernd Krist, Ulrike Weyer-Czernilofsky, Maria Impagnatiello, Matthias Treu, Iris Kauffmann-Hefner, Pilar Garin-Chesa, Andreas Schnapp
-
Publication number: 20030232742Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.Type: ApplicationFiled: November 9, 2001Publication date: December 18, 2003Inventors: Stefan Peters, Dietmar Leipert, Christian Eickmeier, John Edward Park, Martin Lenter, Pilar Garin-Chesa, Juergen Mack
-
Publication number: 20030211979Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP&agr;, and the drug released by the enzymatic activity of FAP&agr; is cytotoxic or cytostatic under physiological conditions.Type: ApplicationFiled: January 3, 2003Publication date: November 13, 2003Applicant: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Stefan Blech, Pilar Garin-Chesa, Martin Lenter, John Edward Park, Stefan Peters, Steffen Breitfelder
-
Patent number: 6613879Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.Type: GrantFiled: April 21, 2000Date of Patent: September 2, 2003Assignees: Boehringer Ingelheim Pharma KG, Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Raymond A. Firestone, Wolfgang J. Rettig, Martin Lenter, Stefan Peters, Pilar Garin-Chesa, Juergen Mack, Dietmar Leipert, John E. Park, Leila A. Telan
-
Publication number: 20030143229Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: ApplicationFiled: June 3, 2002Publication date: July 31, 2003Applicant: Boehringer Ingelheim International GmbHInventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Leger, Jose William Saldanha
-
Publication number: 20030055052Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognised by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions.Type: ApplicationFiled: November 9, 2001Publication date: March 20, 2003Inventors: Stefan Peters, Dietmar Leipert, John Edward Park, Martin Lenter, Pilar Garin-Chesa
-
Patent number: 6518415Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by the murine antibody Lewis Y. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumor types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumors. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.Type: GrantFiled: May 20, 1997Date of Patent: February 11, 2003Assignee: Ludwig Institute for Cancer ResearchInventors: Kathryn Lesley Armour, Francis Joseph Carr, Lloyd J. Old, Elisabeth Stockert, Sydney Welt, Kunio Kitamura, Pilar Garin-Chesa
-
Publication number: 20020155565Abstract: The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP&agr;), said prodrug having a cleavage site which is recognized by FAP&agr;, and said drug being cytotoxic or cytostatic under physiological conditions, wherein said prodrug comprises an oligomeric part comprising at least two amino carboxylic residues, and a cytotoxic or cytostatic part, wherein the C-terminal amino carboxylic residue of the oligomeric part is an acyclic amino acid, the nitrogen atom of the amino function thereof is attached to a substituent being different from a hydrogen atom, and the C-terminal carboxy function thereof is linked to the cytotoxic or cytostatic part by an amide bond.Type: ApplicationFiled: November 9, 2001Publication date: October 24, 2002Inventors: Pilar Garin-Chesa, John Edward Park, Stefan Peters, Dietmar Leipert, Juergen Mack, Martin Lenter
-
Patent number: 6455677Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: GrantFiled: April 29, 1999Date of Patent: September 24, 2002Assignee: Boehringer Ingelheim International GmbHInventors: John Edward Park, Pilar Garin-Chesa, Uwe Bamberger, Wolfgang J. Rettig, Olivier Lèger, Jose William Saldanha
-
Publication number: 20020099180Abstract: The invention relates to antibody proteins which specifically bind fibroblast activating protein alpha (FAP&agr;). The invention further relates to the use of said antibodies for diagnostic and therapeutic purposes as well as processes for preparing said antibodies.Type: ApplicationFiled: March 19, 2001Publication date: July 25, 2002Inventors: Klaus Pfizenmaier, Dieter Moosmayer, Michael Mersmann, Alexej Schmidt, John-Edward Park, Pilar Garin-Chesa
-
Patent number: 6391302Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.Type: GrantFiled: August 7, 2000Date of Patent: May 21, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Thomas Paul Wallace, Francis Carr, Wolfgang J. Rettig, Pilar Garin-Chesa, Lloyd J. Old
-
Publication number: 20020052480Abstract: Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP&agr;) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purposes and methods of producing said antibodies.Type: ApplicationFiled: April 29, 1999Publication date: May 2, 2002Inventors: JOHN EDWARD PARK, PILAR GARIN-CHESA, UWE BAMBERGER, WOLFGANG J. RETTIG, OLIVIER LEGER, JOSE WILLIAM SALDANHA